Short Interest in Axcella Health Inc. (NASDAQ:AXLA) Drops By 44.2%
Short Interest in Axcella Health Inc. (NASDAQ:AXLA) Drops By 44.2%
Axcella Health Inc. (NASDAQ:AXLA – Get Rating) was the target of a significant decrease in short interest in the month of January. As of January 15th, there was short interest totalling 190,000 shares, a decrease of 44.2% from the December 31st total of 340,600 shares. Based on an average daily volume of 1,090,000 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.7% of the shares of the stock are short sold.
阿克塞拉健康公司（NASDAQ：AXLA-獲取評級）是短期利益在一月份顯著減少的目標。截至 1 月 15 日，總共有 19 萬股短期權益，較十二月三十一日共 340,600 股股份下跌 44.2%。以每日平均成交量 1,090,000 股計算，日數佔覆蓋率目前為 0.2 天。目前，該股票的 0.7% 股票賣空。
Institutional Trading of Axcella Health
阿克塞拉健康的機構交易
Hedge funds have recently bought and sold shares of the company. FMR LLC lifted its stake in Axcella Health by 1.1% during the second quarter. FMR LLC now owns 7,886,376 shares of the company's stock valued at $16,009,000 after buying an additional 85,541 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Axcella Health by 24.2% during the third quarter. Dimensional Fund Advisors LP now owns 113,085 shares of the company's stock valued at $194,000 after buying an additional 22,007 shares in the last quarter. Renaissance Technologies LLC lifted its stake in Axcella Health by 13.9% during the second quarter. Renaissance Technologies LLC now owns 55,700 shares of the company's stock valued at $113,000 after buying an additional 6,800 shares in the last quarter. Thrivent Financial for Lutherans purchased a new stake in Axcella Health during the third quarter valued at about $67,000. Finally, Commonwealth Equity Services LLC purchased a new stake in Axcella Health during the third quarter valued at about $34,000. 71.05% of the stock is owned by hedge funds and other institutional investors.
對沖基金最近買賣了該公司的股票。FMR 有限責任公司在第二季度將其在阿克塞拉健康的股份提升了 1.1％。在上一季度額外購買 85,541 股股票後，FMR 有限責任公司現在擁有該公司股票價值 16,009,000 美元的 7,886,376 股股份。維基金顧問 LP 在第三季度將其在阿克塞拉健康的股份提高了 24.2％。維基金顧問 LP 現在擁有該公司股票的 113,085 股，價值為 194,000 美元，在上一季度額外購買了 22,007 股後。文藝復興技術有限責任公司在第二季度取消了在阿克塞拉健康 13.9% 的股份.文藝復興科技有限責任公司現在擁有該公司 55,700 股價值 113,000 美元的股票，在上一個季度額外購買 6,800 股股票後。節儉金融路德會在第三季度購買了阿克塞拉健康的新股份，價值約為 67,000 美元。最後，英聯邦股票服務有限責任公司在第三季度購買了 Axcella Health 的新股份，價值約為 34,000 美元。71.05％ 的股票由對沖基金和其他機構投資者擁有。
Analysts Set New Price Targets
分析師設定新的價格目標
Several equities research analysts recently weighed in on the stock. Chardan Capital reduced their price objective on shares of Axcella Health from $7.00 to $5.00 and set a "buy" rating for the company in a report on Wednesday, November 2nd. SVB Leerink reaffirmed a "market perform" rating and issued a $2.00 price objective (down previously from $6.00) on shares of Axcella Health in a report on Friday, December 16th. Wedbush reaffirmed an "outperform" rating and issued a $6.00 price objective on shares of Axcella Health in a report on Wednesday, November 2nd. Finally, HC Wainwright downgraded shares of Axcella Health from a "buy" rating to a "neutral" rating in a report on Thursday, December 15th.
幾位股票研究分析師最近對股票進行了權衡。佳丹資本將其對阿克塞拉健康股份的價格目標從 7.00 美元降低至 5.00 美元，並在 11 月 2 日（星期三）的一份報告中為該公司設定了「買入」評級。在 12 月 16 日（星期五）的一份報告中，SVB Leerink 重申了「市場表現」評級，並對阿克塞拉健康的股票發布了 2.00 美元的價格目標（以前從 6.00 美元下跌）。Wedbush 在 11 月 2 日（星期三）的一份報告中重申了「跑贏大市」評級，並對阿克塞拉健康的股票發布了 6.00 美元的價格目標。最後，在 12 月 15 日（星期四）的報告中，HC 溫賴特將 Axcella 健康的股票從「買入」評級降級為「中性」評級。
Axcella Health Price Performance
阿克塞拉健康價格表現
Axcella Health (NASDAQ:AXLA – Get Rating) last issued its quarterly earnings results on Tuesday, November 1st. The company reported ($0.34) earnings per share for the quarter, beating analysts' consensus estimates of ($0.37) by $0.03. As a group, equities research analysts forecast that Axcella Health will post -1.39 EPS for the current fiscal year.
阿克塞拉健康 (NASDAQ: AXLA — 獲取評級) 上次公佈其季度盈利業績於 11 月 1 日（星期二）。該公司報告了本季度每股盈利（0.34 美元），超過分析師對 0.37 美元的共識估計（0.37 美元）。作為一個集團，股票研究分析師預測 Axcella Health 將在本財政年度實現 -1.39 每股盈利。
About Axcella Health
關於艾克塞拉健康
(Get Rating)
(取得評分)
Axcella Health, Inc is a biotechnology company. It engages in the research and development of treatment for diseases and improves health using endogenous metabolic modulator, or EMM, and compositions. Its product pipeline includes AXA1665, for the reduction in risk of recurrent overt hepatic encephalopathy, and AXA1125, for non-alcoholic steatohepatitis.
阿克塞拉健康公司是一家生物技術公司。它從事治療疾病的研究和開發，並改善健康使用內源性代謝調節器, 或 EMM, 和組合物.其產品線包括 AXA1665，用於降低復發性肝性腦病的風險，以及用於非酒精性脂肪性肝炎的 AXA1125。
See Also
另請參閱
- Get a free copy of the StockNews.com research report on Axcella Health (AXLA)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
- 獲取有關阿克塞拉健康（AXLA）的研究報告的免費副本
- 市場節拍週的回顧 — 1/23-1/27
- 為什麼清醒在一天內飆升近 100％
- 乘坐這些鐵路股票以獲得增長和收入
- ASML 今年看到籌碼需求上升，提高了銷售觀點
- KLA 公司：陷入困境的半市場中的實力
Receive News & Ratings for Axcella Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axcella Health and related companies with MarketBeat.com's FREE daily email newsletter.
接收阿克塞拉健康日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Axcella Health 及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。